# Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV

> **NCT01535885** · PHASE1 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 25 (actual)

## Conditions studied

- Epstein-Barr Virus Infections
- Adenovirus
- Cytomegalovirus Infections

## Interventions

- **BIOLOGICAL:** Cytotoxic T Lymphocytes

## Key facts

- **NCT ID:** NCT01535885
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2019-10
- **Final completion:** 2019-10
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01535885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01535885, "Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01535885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*